LONDON, June 23, 2015 /PRNewswire/ -- Among conjugated drugs in oncology, antibody-drug conjugates (ADCs) are by far getting the most attention as a new drug class. Owing to improved technology and appropriate targeting, the clinical application of ADCs is accelerating rapidly. But antibodies are not the only kind of compound one could conjugate small molecules to, nor the only class of compounds which one can yield targeted therapy from. This drug pipeline update gives a 360 degree account on what conjugated drugs in oncology entails, from antibody-drug conjugates to conjugated siRNAs and fusion proteins. Meet drugs which linker technology is responsive to various factors in the tumor microenvironment or 2-part drug targeting technology which concentrates the therapeutic agent from a low and harmless dose in the blood to a high therapeutic dose specifically in the target tissue. The degree of innovation among conjugated drugs in oncology is truly amazing and inspiring for any stakeholder in cancer drug development.
There are today 265 companies plus partners developing 366 conjugated drugs in oncology drugs in 956 developmental projects in cancer. In addition, there are 2 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 139 drugs. Conjugated Drugs In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 210 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 195 out of the 198 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 50 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.
How May Drug Pipeline Update Be of Use?
* Show investors/board/management that you are right on top of drug development progress in your therapeutic area. * Find competitors, collaborations partners, M&A candidates etc. * Jump start competitive drug intelligence operations * Excellent starting point for world wide benchmarking * Compare portfolio and therapy focus with your peers * Speed up pro-active in-/out licensing strategy work * Fast and easy way of tracking drugs using search engines; just one click from inside the application and you may search the World Wide Web and PubMed for any drug. Drug Pipeline Update is delivered to you as a downloadable application, which requires no installation on your computer. Please read more about application features and system requirements below.
Drug Pipeline Update at a Glance
Includes more than 265 principal companies plus their collaborators. There is direct access from inside the application to web pages of all principal companies.
Note: You are able to sort and find drugs according to companies and partners from drop-down menus in the application. You may also sort and find drugs according to country of companies.
Drug name & Synonyms
Lists commercial, generic and code names for drugs.
This Drug Pipeline Update contains 366 conjugated drugs in oncology drugs in development, which have a total of 956 developmental projects in cancer. In addition there are suspended and ceased drugs.
Pipeline Breakdown According to Number of Drugs
Phase III# 26
Phase II# 89
Phase I# 100
No Data# 14
Note: You are able to sort and find drugs according to developmental stage from drop-down menu in the application.
Included conjugated drugs in oncology drugs are also in development for 181 other indications, where of 129 are different cancer indications.
Note: You are able to find and sort drugs according to type of indication from drop-down menu in the application.
All targets are cross-referenced with the Catalogue of Somatic Mutations in Cancer (COSMIC). It is designed to store and display somatic mutation information and related details and contains information relating to human cancers. To date 195 out of the 198 studied drug targets so far have been recorded with somatic mutations and the software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information.
The identity of available biological structures on 143 drug targets was retrieved from the RCSB Protein Databank for you to easily review the 2289 structures available today among drug targets.
Identified drugs are linked to more than 210 different targets, divided into 50 classifications of molecular function:
- ATPase activity
- Auxiliary transport protein activity
- B cell receptor activity
- Carboxypeptidase activity
- Catalytic activity
- Cell adhesion molecule activity
- Chaperone activity
- Chemokine activity
- Cofactor binding
- Cytokine activity
- Deaminase activity
- DNA binding
- DNA topoisomerase activity
- DNA-directed DNA polymerase activity
- DNA-directed RNA polymerase activity
- Extracellular matrix structural constituent
- G-protein coupled receptor activity
- Growth factor activity
- Guanylate cyclase activity
- Heat shock protein activity
- Hormone activity
- Hydrolase activity
- Kinase activity
- Kinase regulator activity
- Ligand-dependent nuclear receptor activity
- Ligase activity
- Lipid kinase activity
- Metallopeptidase activity
- MHC class I receptor activity
- Molecular function unknown
- Oxidoreductase activity
- Peptide hormone
- Phosphoric diester hydrolase activity
- Protein binding
- Protein serine/threonine kinase activity
- Protein-tyrosine kinase activity
- Receptor activity
- Receptor binding
- Receptor signaling complex scaffold activity
- Receptor signaling protein serine/threonine kinase activity
- RNA binding
- Serine-type peptidase activity
- Structural constituent of cytoskeleton
- Transcription factor activity
- Transcription regulator activity
- Transferase activity
- Translation regulator activity
- Transmembrane receptor activity
- Transmembrane receptor protein tyrosine kinase activity
- Transporter activity
Identified targets are categorized into 24 different primary and alternate sub-cellular localizations:
- Clathrin-coated vesicle
- Cytoplasmic vesicle
- Endoplasmic reticulum
- Golgi apparatus
- Integral to membrane
- Membrane fraction
- Mitochondrial matrix
- Perinuclear vesicle
- Peroxisomal matrix
- Plasma membrane
- Sarcoplasmic reticulum
- Secretory granule
- Zymogen granule
Note: You are able to find and sort drugs according to target gene name, protein name, molecular function of target, target localization, presence of mutations and availability of biological structures of target from drop-down menus in the application.
Target Expression Profile
Direct links are provided from inside the application to 268 protein expression profiles of 178 drug targets in various human tissues and cancer types, cell lines and primary cells, including up to:
- 48 different normal tissue types
- 20 different types of cancer
- 47 cell lines
- 12 samples of primary blood cells
Identified targets have been cross referenced against their involvement in different cellular pathways, according to BioCarta, KEGG, NCI-Nature and NetPath.
- BioCarta# 183 Pathways
- KEGG# 164 Pathways
- NCI-Nature# 211 Pathways
- NetPath# 27 Pathways
Note: You are able to find and sort drugs according to targeted pathways from drop-down menus in the application.
In total there are different drug mechanism of action represented in this Drug Pipeline Update.
Note: You are able to find and sort drugs according to mechanism of action from drop-down menu in the application.
Identified drug compounds are described by:
Compound type, Chemical name, CAS Number and molecular weight
Note: You are able to sort and find drugs according to compound type from drop-down menu in the application.
Progress analysis and review of drug development. A typical drug profile reports on, depending on stage of development and available information:
Drug Name & Synonyms
Presentation of drug name and synonyms
Principal Company & Partners
Presentation of principal company and partners
Target and Molecular Function of Target
Described target(s) is/are presented with:
Official Gene Symbol – Chromosome Location – Gene & Protein Name – Molecular Function
Described target(s) is/are presented with primary and alternate localizations.
Target Expression Profiles
Links to protein expression profile(s) of target(s) in various human tissues, cell lines and primary cells, including up to:
48 different normal tissue types
20 different types of cancer
47 cell lines
12 samples of primary blood cells
All targets are cross-referenced with the Catalogue of Somatic Mutations in Cancer (COSMIC). It is designed to store and display somatic mutation information and related details and contains information relating to human cancers.
The identity of available biological structures on drug targets was retrieved from the RCSB Protein Databank for you to easily review what available structures of drug targets exist.
Described target(s) is/are matched for the involvement in cellular pathways according to BioCarta, KEGG, NCI-Nature and NetPath.
Drug mechanism of action
Summary field of developmental projects for the drug, including indication, developmental stage and status.
Cancer, myeloma – Phase II Clinical Trial – Active
Cancer, prostate – Phase III Clinical Trial – Ceased
Short introduction to drug
Compound type, Chemical name, CAS Number and molecular weight
Available patent information related to the drug is presented here.
Fillings and Approvals
Approvals and submissions
Deals & Licensing
Collaborations and deals
Availability for licensing
Phase IV Data
Available Phase IV development data, developmental history and scientific data.
Phase III Data
Available Phase III development data, developmental history and scientific data.
Phase II Data
Available Phase II development data, developmental history and scientific data.
Phase I Data
Available Phase I development data, developmental history and scientific data.
Phase 0 Data
Available Phase 0 development data, developmental history and scientific data.
Available preclinical development data, developmental history and scientific data.
Available discovery development data, developmental history and scientific data.
Search, Find and Filter Panel with Initial Result Presentation
With this panel you can define your selectivity in each drug search with up to 24 different drug specific parameters. Each parameter has multi-select options to them and can be used as either an inclusion parameter or exclusion parameter.
The initial result table is a dynamic sortable table which gives you a fast overview of found results and can be narrowed down further by your own additional keywords.
Direct linkage from inside the application to related internet resources
- Drug data is linked to search engines like Google and PubMed
- Drug target data is linked directly to BioCarta, Human Protein Atlas, KEGG, NCI-Nature, NetPath etc.
- Direct links to company web pages of companies
Dynamic Report Generator
Our dynamic report generator lets you with ease and speed generate html reports directly in your web browser (Internet Explorer and FireFox), whether it is a single drug profile or an entire search you want have a report of.
- Operating system: Windows (2000/XP/Vista/7/8) for Mac Users the service is only available online
- Browser Application (Internet Explorer, Firefox, Chrome, Safari)
- Internet access (to access related internet resources)
Download the full report: https://www.reportbuyer.com/product/1601234/
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
For more information:
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48